Duloxetine or venlafaxine – what to choose in a psychiatrist’s practice? Review article
Article Sidebar
Published:
May 31, 2026
Keywords:
venlafaxine, duloxetine, SNRI, depression, anxiety, pain
Main Article Content
Abstract
Venlafaxine and duloxetine belong to the group of serotonin and norepinephrine reuptake inhibitors. Both drugs have documented efficacy in the treatment of major depressive episodes and anxiety disorders; however, they differ in their pharmacological profile, dose-dependent effects, range of pain-related indications, and certain aspects of tolerability. Venlafaxine is a drug whose clinical mechanism is clearly dose-dependent: at lower doses it acts mainly serotonergically, whereas the noradrenergic effect emerges as the dose is increased. Duloxetine, although it also shows greater affinity for the serotonin transporter than for the norepinephrine transporter, has a more balanced profile than venlafaxine and, in clinical practice, does not require the same as venlafaxine of dose titration to achieve noradrenergic activity. This is relevant in patients in whom rapid attainment of a therapeutic dose, a simple dosing regimen, limitation of adverse effects associated with dose escalation, and simultaneous treatment of depression, anxiety, and pain are important.
Article Details
How to Cite
Dudek, D. (2026). Duloxetine or venlafaxine – what to choose in a psychiatrist’s practice?. Medycyna Faktow (J EBM), 19(1(70), 31-37. https://doi.org/10.24292/01.MF.0126.4
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Samochowiec J, Dudek D, Kucharska-Mazur J et al. Leczenie farmakologiczne epizodu depresji i zaburzeń depresyjnych nawracających – wytyczne Polskiego Towarzystwa Psychiatrycznego i Konsultanta Krajowego ds. Psychiatrii Dorosłych. Psychiatr Pol. 2021; 55(2): 235-59. http://doi.org/10.12740/PP/OnlineFirst/132496.
2. Perahia DGS, Pritchett YL, Kajdasz DK et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42(1): 22-34. http://doi.org/10.1016/j.jpsychires.2007.01.008.
3. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66. http://doi.org/10.1016/S0140-6736(17)32802-7.
4. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001; 25(6): 871-80. http://doi.org/10.1016/S0893-133X(01)00298-6.
5. Fagiolini A, Cardoner N, Pirildar S et al. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder. Expert Opin Pharmacother. 2023; 24(15): 1715-23. http://doi.org/10.1080/14656566.2023.2242264.
6. Ferreira GE, Abdel-Shaheed C, Underwood M et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ. 2023; 380: e072415. http://doi.org/10.1136/bmj-2022-072415.
7. Wernicke J, Lledó A, Raskin J et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007; 30(5): 437-55. http://doi.org/10.2165/00002018-200730050-00007.
8. Radovanovič M, Pišljar M, Barbič-Žagar B et al. Efficacy and Safety of Duloxetine in the Treatment of Depression, Generalized Anxiety Disorder and Diabetic Peripheral Neuropathic Pain. Viceversa 2017; 63: 60-72.
9. Čelofiga A, Barbič-Žagar B, Vrzel M et al. Efficacy and safety of Duloxetine (Dulsevia®) in the Dose of 90 mg in Patients with Major Depressive Disorder or Generalized Anxiety Disorder in Clinical Practice. Viceversa 2020; 65: 66-78.
10. Montejo AL, Perahia DGS, Spann ME et al. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med. 2011; 8(3): 773-82. http://doi.org/10.1111/j.1743-6109.2010.02113.x.
11. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29(3): 259-66.
12. Wise TN, Perahia DGS, Pangallo BA et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006; 8(5): 269-78. http://doi.org/10.4088/PCC.v08n0503.
13. Henssler J, Schmidt Y, Schmidt U et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024; 11(7): 526-35. http://doi.org/10.1016/S2215-0366(24)00133-0.
14. Perahia DGS, Kajdasz DK, Desaiah D et al. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2005; 89(1–3): 207-12. http://doi.org/10.1016/j.jad.2005.09.003.
15. Wasilewski D, Wojnar M, Chatizow J. Depresja a ból: ogólnopolskie badanie epidemiologiczne. Psychiatr Pol. 2010;44(3): 435-45.
16. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003; 163(20): 2433-45.
17. Raskin J, Wiltse CG, Siegal A et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007; 164(6): 900-9. http://doi.org/10.1176/ajp.2007.164.6.900.
18. Wohlreich MM, Mallinckrodt CH, Watkin JG et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr. 2004; 4: 11. http://doi.org/10.1186/1471-2318-4-11.
2. Perahia DGS, Pritchett YL, Kajdasz DK et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42(1): 22-34. http://doi.org/10.1016/j.jpsychires.2007.01.008.
3. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66. http://doi.org/10.1016/S0140-6736(17)32802-7.
4. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001; 25(6): 871-80. http://doi.org/10.1016/S0893-133X(01)00298-6.
5. Fagiolini A, Cardoner N, Pirildar S et al. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder. Expert Opin Pharmacother. 2023; 24(15): 1715-23. http://doi.org/10.1080/14656566.2023.2242264.
6. Ferreira GE, Abdel-Shaheed C, Underwood M et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ. 2023; 380: e072415. http://doi.org/10.1136/bmj-2022-072415.
7. Wernicke J, Lledó A, Raskin J et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007; 30(5): 437-55. http://doi.org/10.2165/00002018-200730050-00007.
8. Radovanovič M, Pišljar M, Barbič-Žagar B et al. Efficacy and Safety of Duloxetine in the Treatment of Depression, Generalized Anxiety Disorder and Diabetic Peripheral Neuropathic Pain. Viceversa 2017; 63: 60-72.
9. Čelofiga A, Barbič-Žagar B, Vrzel M et al. Efficacy and safety of Duloxetine (Dulsevia®) in the Dose of 90 mg in Patients with Major Depressive Disorder or Generalized Anxiety Disorder in Clinical Practice. Viceversa 2020; 65: 66-78.
10. Montejo AL, Perahia DGS, Spann ME et al. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med. 2011; 8(3): 773-82. http://doi.org/10.1111/j.1743-6109.2010.02113.x.
11. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29(3): 259-66.
12. Wise TN, Perahia DGS, Pangallo BA et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006; 8(5): 269-78. http://doi.org/10.4088/PCC.v08n0503.
13. Henssler J, Schmidt Y, Schmidt U et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024; 11(7): 526-35. http://doi.org/10.1016/S2215-0366(24)00133-0.
14. Perahia DGS, Kajdasz DK, Desaiah D et al. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2005; 89(1–3): 207-12. http://doi.org/10.1016/j.jad.2005.09.003.
15. Wasilewski D, Wojnar M, Chatizow J. Depresja a ból: ogólnopolskie badanie epidemiologiczne. Psychiatr Pol. 2010;44(3): 435-45.
16. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003; 163(20): 2433-45.
17. Raskin J, Wiltse CG, Siegal A et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007; 164(6): 900-9. http://doi.org/10.1176/ajp.2007.164.6.900.
18. Wohlreich MM, Mallinckrodt CH, Watkin JG et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr. 2004; 4: 11. http://doi.org/10.1186/1471-2318-4-11.